SIGA receives approval from the FDA for intravenous formulation of Tpoxx (tecovirimat)

SIGA Technologies

19 May 2022 - FDA approval provides an important option for those unable to take oral formulation of Tpoxx.

SIGA Technologies today announced that the U.S. FDA approved the intravenous formulation of Tpoxx for the treatment of smallpox. 

The intravenous formulation is an important option for those who are unable to swallow the oral capsules of Tpoxx.

Read SIGA Technologies press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US